The global pediatric perfusion market size was valued at US$ 574.7 Mn in 2023 and is expected to reach US$ 875.3 Mn by 2031 growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Global Pediatric Perfusion Market Regional Insights:
Analyst View: The pediatric perfusion market is expected to witness steady growth over the next few years. The rising prevalence of congenital heart diseases among children is a major growth driver. Improving healthcare infrastructure and growing awareness about pediatric cardiac treatments are further fueling demand. Advanced perfusion systems offering enhanced safety and efficacy are gaining adoption. However, high costs associated with pediatric cardiac procedures can hamper market growth to an extent. North America currently dominates the pediatric perfusion market and is expected to maintain its leading position. This can be attributed to the presence of advanced healthcare facilities, supportive reimbursement structure, and growing awareness levels in the region. Asia Pacific is projected to emerge as the fastest growing regional market over the forecast period. Increasing medical tourism, rising healthcare expenditures, and growing incidences of congenital heart diseases are favoring market expansion in Asia Pacific. On the product front, heart-lung machines are likely to remain the largest revenue generator owing to wide utilization in various cardiac procedures. However, oxygenators are expected to witness fastest growth on account of the introduction of advanced products with enhanced safety and performance features. Non-facility-based perfusion services are gaining popularity and offering new opportunities for market players. Collaborations aimed at the development of compact and affordable pediatric perfusion systems also present avenues for growth.
Figure 1. Global Pediatric Perfusion Market Share (%), by Region, 2024
To learn more about this report, Request sample copy
Global Pediatric Perfusion Market Drivers:
The increasing incidence of cardiovascular diseases (CVDs) in the pediatric population: The increasing incidence of cardiovascular diseases (CVDs) in the pediatric population is indeed a driving force behind the growth of the pediatric perfusion market. With the rise in congenital heart defects, cardiomyopathies, and other cardiac conditions affecting children, there is a growing demand for expert cardiopulmonary support during surgical interventions. The rise in cardiac conditions necessitates a higher volume of surgical procedures, directly increasing the demand for perfusion technologies. Increasing complexity of congenital heart surgeries requires advanced perfusion techniques and equipment, fueling market innovation and growth. Advancements in pediatric perfusion contribute to higher success rates of cardiac surgeries, garnering trust among healthcare professionals and encouraging the uptake of these procedures. The specific physiological parameters of children require specialized perfusion systems, creating a niche market for tailored solutions. Improvements in the early diagnosis of cardiovascular conditions have led to a broader patient base seeking treatment at earlier stages, augmenting the demand for pediatric perfusion services. Public health efforts to address the burden of pediatric cardiovascular disease may include equipping hospitals with the necessary technologies, such as perfusion systems, which supports market growth. Players in the market can leverage this trend by focusing on developing and providing pediatric-specific perfusion equipment and disposables, investing in training and education for health professionals, and engaging in research and development to improve the safety and effectiveness of perfusion in pediatric cardiac care. For instance, in January 2024, according to data provided by Indian Academy of Pediatrics, congenital heart disease (CHD) is the most frequently occurring congenital disorder, responsible for 28% of all congenital birth defects. The birth prevalence of CHD was reported to be 8-12/1,000 live births in 2018. Considering a rate of 9/1,000, about 1.35 million babies are born with CHD each year globally.
Increasing government initiatives and funding: Increasing government initiatives and funding are indeed pivotal factors that are expected to drive growth in the pediatric perfusion market. As governments around the world recognize the importance of enhancing pediatric cardiac care, there is an increasing allocation of resources and implementation of policies to support the healthcare needs of children with cardiovascular conditions. Government funding often goes towards building and upgrading healthcare facilities, including those required for complex surgeries that necessitate pediatric perfusion, such as heart-lung machines and other supporting equipment. Initiatives that provide financial aid or reimbursement for pediatric surgeries can make these life-saving procedures more accessible and affordable for a wider population. Funding and government-led programs aimed at educating and training medical professionals, including pediatric perfusionists, can expand the workforce capable of delivering high-quality care. Government grants for research can stimulate innovation in the pediatric perfusion field, leading to the development of new and improved technologies that enhance surgical outcomes. Awareness campaigns funded by governments can increase the visibility of pediatric cardiovascular issues and the treatments available, encouraging early diagnosis and treatment. Streamlining regulatory processes for the approval of new medical devices can expedite the availability of advanced pediatric perfusion equipment in the market. Government initiatives that foster collaboration can lead to shared knowledge and resources, further promoting the growth of sophisticated healthcare services like pediatric perfusion. In essence, proactive government involvement can significantly reduce the barriers to quality pediatric cardiac care, directly influencing the scope and scale of the pediatric perfusion market. For market participants, staying abreast of such initiatives and engaging with public entities can be crucial for aligning their business strategies with the evolving landscape.
The emergence of new technologies in pediatric perfusion: The emergence of recent technology in pediatric perfusion is certainly a massive driving force for the pediatric perfusion market. As technological improvements evolve, they create approximately improvements in perfusion system and strategies which are higher ideal for the particular physiological necessities of babies and kids present process cardiac surgery. Development of smaller perfusion circuits and additives designed especially for pediatric patients, decreasing blood product utilization and minimizing the inflammatory reaction frequently visible with large circuits. Enhanced monitoring and control systems in heart-lung machines that allow for more precise management of delicate pediatric perfusion cases result in better patient outcomes. The introduction of safer materials with superior biocompatibility reduce the risk of adverse reactions and improve long-term outcomes for pediatric patients. Use of smart sensors and real-time data analytics to closely monitor patient parameters and perfusion status provide vital information to the perfusionists and surgical team. Advancements in oxygenator and filter technology enhance gas exchange and filtration efficiency, critical for supporting small patients with limited tolerance for physiological fluctuations. Incorporation of robotic elements and automated processes to assist in repetitive or complex tasks enhances precision and reliability of the perfusion process. Technologies aimed at reducing postoperative complications and improving overall outcomes can increase the success rate of pediatric cardiac surgeries and encourage their utilization. The continued evolution of these technologies is fostering a more dynamic and capable pediatric perfusion market. They also open doors for market expansion as improved technologies can mitigate previous risks associated with pediatric perfusion, making surgery a viable option for a broader range of cases. Market players can capitalize on this trend by investing in R&D, collaborating with healthcare professionals to understand clinical needs, and focusing on innovation to meet the stringent demands of pediatric perfusion.
Technological advancements: Technological advancements are indeed a potent catalyst propelling the pediatric perfusion market forward. As technology in healthcare continues to progress, the capabilities of perfusion systems are enhanced, particularly in the context of pediatric care. Innovations in this field are critical because children, especially neonates and infants, present unique challenges due to their smaller anatomical size and different physiological responses compared to adults. Devices specifically designed to accommodate the limited blood volume of pediatric patients reduce the risk of hemodilution and blood transfusions, which is especially important in newborns and small children. Technological improvements often come with better safety features, reducing the risk of complications such as air embolism and blood trauma during surgery. The integration of advanced sensors and monitoring systems allows for more precise management of vital parameters during pediatric cardiac surgeries, improving outcomes and patient safety. Advances in materials used for perfusion equipment can minimize the body's inflammatory response and enhance biocompatibility, which is crucial for the sensitive immune systems of children. Automated perfusion systems can standardize procedures to a certain extent, potentially reducing the variability that comes with manual operations and improving overall results. Software for planning and simulating surgeries can help in individualizing perfusion strategies for pediatric patients, leading to better-prepared surgeries with optimized results. The use of 3D printing technology in creating customized components of perfusion systems allows for better fit and customization, which can be particularly advantageous for pediatric patients. These advancements are bolstering the pediatric perfusion market by providing more effective, safer, and tailored solutions for pediatric cardiac surgery.
Global Pediatric Perfusion Market Opportunities:
Global Pediatric Perfusion Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2023: | US$ 574.7 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 - 2031 |
Forecast Period 2024 to 2031 CAGR: | 5.4% | 2031 Value Projection: | US$ 875.3 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Medtronic, GE Healthcare, LivaNova, Inc., Getinge, Braile Biomedica, XENIOS AG, BL Lifesciences, Terumo Corporation, 3M, Koninklijke Philips N.V., EUROSETS, Merck KGaA, Stryker, Cardinal Health, Nonin, and Sorin Group USA, Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Pediatric Perfusion Market Trends:
Global Pediatric Perfusion Market Restraints:
Recent Developments:
New Product Launches & Approval:
In March 2023, LivaNova PLC, a medical technology and innovation company, announced that it has received the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz Heart-Lung Machine (HLM). LivaNova PLC initiated the commercial launch of Essenz in the U.S.
In January 2022, XVIVO, a medical technology company, received ‘510(k) clearance’ from the U.S. FDA for its portable organ perfusion system, a Kidney Assist Transport. It facilitates donor kidneys' continuous hypothermic pulsatile perfusion using an oxygenated preservation solution throughout the transportation process from the donor to the recipient in transplant procedures.
In November 2021, Dongguan Kewei Medical Instrument Co., Ltd., a subsidiary of MicroPort Scientific Corporation, a medical device company, received approval of National Medical Products Administration (NMPA) of China for the Vitasprings Spiral Diversion Integrated Membrane Oxygenator. Vitasprings is a product developed in China that imitates the function of the lungs in cardiopulmonary bypass and adopts an innovative hemodynamic structure featuring a spiral flow guide and secondary diversion combined with a vortex exhaust design, which can reduce damage to blood cells.
Acquisition, Collaboration, and Partnerships:
In September 2022, CHS USA Inc., a privately-held medical device manufacturer, announced the acquisition of SandBox Medical LLC, the manufacturer and source for JollyPop Pacifiers and other products designed for premature babies and full-term newborns. This acquisition will increase CHS USA Inc.'s presence in the Neonatal Intensive Care Unit (NICU) and pediatric market, while providing innovative products for premature babies and full-term newborns.
In September 2020, XVIVO, a medical technology company, announced acquisition of Organ Assist B.V., a company that focuses primarily on developing machines and consumables for liver and kidney perfusion. Through the acquisition, XVIVO became the first organ preservation and evaluation company to be actively involved in all major organs, which accelerates the company’s strategy of becoming a global all organ provider.
Figure 2. Global Pediatric Perfusion Market Share (%), By Product Type, 2024
To learn more about this report, Request sample copy
Top Companies in the Global Pediatric Perfusion Market:
Definition: Pediatric perfusion refers to the specialized practice of using cardiopulmonary bypass and extracorporeal circulation techniques during cardiac surgery for infants and children. It involves the use of a heart-lung machine and associated equipment to maintain blood flow and oxygenation to the body when the child's heart or lungs are unable to function properly or need to be temporarily stopped during surgery. This practice is crucial in treating congenital heart defects, which are structural heart problems present at birth, as well as other pediatric cardiac conditions requiring surgical intervention. Pediatric perfusionists are skilled professionals trained to handle these sophisticated devices, and they play a critical role in the success of pediatric cardiac surgical procedures. Due to the smaller size and unique physiological characteristics of pediatric patients, the equipment and procedures used in pediatric perfusion are specifically designed to be more precise and gentle compared to adult perfusion techniques. This field demands a high level of expertise due to the complexities and delicacies involved in managing the circulatory needs of children and ensuring their safety throughout the surgical process.
Pediatric perfusion refers to specialized procedures that utilize extracorporeal circulation techniques to oxygenate and circulate blood outside the body during heart surgery in children. There are various perfusion products and equipment required to effectively support the cardiovascular system during such complex surgeries.
The key products used in pediatric perfusion include heart-lung machines, oxygenators, pumps, cannula, and tubing sets. Heart-lung machines integrate a pump and oxygenator to circulate and oxygenate the child's blood outside their body during surgery. Oxygenators infuse oxygen and remove carbon dioxide from blood. Pumps are crucial to drive blood flow through the circuit while cannula provides vascular access points. Tubing sets connect all components to form a fully-integrated perfusion circuit.
Each product type has its advantages but also disadvantages. For example, while heart-lung machines effectively support heart and lung function, they are also large, expensive, and require specialized personnel to operate. Oxygenators efficiently oxygenate blood but surface area limitations may impact gas exchange in small infants. Pumps and cannula introduce foreign surfaces that require careful biocompatibility. The perfusion circuit complexity also introduces risks of air embolism or component malfunction. Advancements in miniaturization and safety features aim to reduce downsides, but pediatric perfusion still requires specialized professional oversight.
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients